Finding a solution for AMR
Antimicrobial resistance (AMR) is a major global threat to human and animal health. Medicines that were once effective treatments for disease are becoming less so, leading to a reduced ability to successfully treat infections. The EU-funded ABOLED project is investigating the commercial viability of an alternative approach to this problem. AMR is responsible for an estimated 33 000 deaths per year in the EU. It is also estimated that AMR costs the EU EUR 1.5 billion per year in healthcare costs and productivity losses. Only 25 % of countries have implemented a national policy to tackle AMR. Less than 40 % of countries have put in place infection prevention and control programmes for AMR.
Fields of science
Funding SchemeERC-POC-LS - ERC Proof of Concept Lump Sum Pilot
KY16 9AJ St Andrews
See on map